St. Jude Children’s Research Hospital concluded the Total Therapy Study 16 evidencing the ability to successfully reduce the rate of central nervous system (CNS) relapse to 1.8% for acute lymphoblastic leukemia (ALL) in children. The Problem: ALL Relapse Despite...
ALL
Category
Rutgers Cancer Institute of New Jersey Secures Grants & Pursues T-Cell Acute Lymphoblastic Leukemia
Rutgers Cancer Institute of New Jersey received over $2 million in grants recently to study potential treatment targets for a rare and aggressive blood cancer called T-cell acute lymphoblastic leukemia (T-ALL). The recent grant awards were reported by Rutgers Cancer...
Children’s Hospital LA Researcher Awarded $1.2 Million to Study Leukemia Drug Resistance
Children’s Hospital Los Angeles (CHLA) investigator Yong-Mi Kim MD, PhD, MPH received $1.2 million to study drug resistance for leukemia. The investigator notes that leukemia cells can hide in bones; in fact, most relapses occur in bone marrow. The research funds will...
Generon Launches Phase I Trial of A-319 for ALL & B-cell Cancer Patients in China
China’s regulatory agency has approved the launch of Genron’s Phase I clinical trial to test its immunotherapy candidate, A-319, in patients with acute lymphoblastic leukemia (ALL) and B-cell lymphoma. A-319 is an antibody that binds the two targets at the same time:...
CHOP Investigators Present Positive Updated Efficacy & Safety Data on Novartis’ Kymriah
As reported in PR Newswire, Children’s Hospital of Philadelphia (CHOP) investigators presented updated efficacy and safety data on Kymriah (tisagenlecleucel)—the first ever U.S FDA approved personalized CAR T-cell gene immunotherapy for aggressive blood cancers at the...